bevacizumab + 5-fluorouracil + leucovorin + oxaliplatin
Phase 2/3Terminated 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastrointestinal Carcinoid Tumor
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor
Trial Timeline
Jun 8, 2005 → Feb 1, 2016
NCT ID
NCT00227617About bevacizumab + 5-fluorouracil + leucovorin + oxaliplatin
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatin is a phase 2/3 stage product being developed by Sanofi for Gastrointestinal Carcinoid Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT00227617. Target conditions include Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00227617 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Gastrointestinal Carcinoid Tumor